Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 585

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 585
---
 to the closing have not been satisfied       
 or waived by the nine-month anniversary of the date of the Merger Agreement, subject to certain  
 extension options available to Denali.                                                           |
| ● | By                                                                                               
 either Longevity or Denali if any governmental authority of competent jurisdiction has issued    
 an order that has become final and non-appealable and has the effect of making consummation      
 of the Merger Transactions illegal or otherwise preventing or prohibiting consummation of        
 the Merger Transactions.                                                                         |
| ● | By                                                                                               
 the non-breaching party if there is a material breach by one or more of the other parties        
 of any of their respective representations, warranties, covenants or agreements contained        
 in the Merger Agreement, or if any such representation or warranty shall have become untrue      
 or inaccurate and the breach or inaccuracy is incapable of being cured or is not cured within    
 the timeframes specified in the Merger Agreement.                                                |
| ● | By                                                                                               
 Denali if there has been a Material Adverse Effect (as defined in the Merger Agreement) on       
 Longevity and the Target Companies, taken as a whole, following the date of the Merger Agreement 
 which is uncured within the time frame specified in the Merger Agreement.                        |
| ● | By                                                                                               
 either Longevity or Denali if any of the required proposals fail to receive the requisite        
 vote for approval by Denali’s shareholders.                                                      |

First Amendment to the C&E Agreement

On January 25, 2023, the Company entered into amendments to the C&E Agreements with each of the Target Companies and each of the Target Companies’ respective shareholders and unitholders pursuant to which certain provisions of the C&E Agreements were amended to, among other things: modify the aggregate valuation assigned to Longevity reflecting the Acquisition Transactions to match that agreed to in the Merger Agreement, modify the allocation of the transaction consideration among the Target Companies to match that agreed to in the Merger Agreement, modify the minimum cash balance at closing of the Business Combination to match that agreed to in the Merger Agreement, and conform certain representations, warranties, covenants, closing conditions, termination provisions, and other provisions of the C&E Agreements to the Merger Agreement.

| F-65 |

longevity biomedical, inc.

notes to the financial statements

December 31, 2023 and 2022

Second Amendment to the C&E Agreement

On June 26, 2023 the C&E Agreements were